TEVA May 2024 11.500 put
| Previous close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0000 |
| Ask | 1.2700 |
| Strike | 11.50 |
| Expiry date | 2024-05-03 |
| Day's range | 0.0600 - 0.0600 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
- Reuters
UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue risea
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose. The world's largest generic drugmaker said on Wednesday it earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Teva said its bottom line was hurt mainly by higher impairments of tangible assets largely related to the classification of a business in its international markets segment as held for sale, as well as restructuring costs.
ReutersTeva Pharm Q1 profit misses estimates, revenue risea
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose. The world's largest generic drugmaker said on Wednesday it earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Teva said its bottom line was hurt mainly by higher impairments of tangible assets largely related to the classification of a business in its international markets segment as held for sale, as well as restructuring costs.
Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEL AVIV, Israel, May 08, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
